1. PRESENTATION ON
RANBAXY
PRESENTED BY:
SHILPI
BHAWNA
MEGHA
TANVI
5/8/2012 1

2. 5/8/2012 2

3. 5/8/2012 3

4. Company Profile
 Ranbaxy was incorporated in 1961 and went public in 1973.
 Ranbaxy Laboratories Limited (Ranbaxy), India's largest
pharmaceutical company.
 It is an integrated, research based, international pharmaceutical
company, producing a wide range of quality, affordable generic
medicines, trusted by healthcare professionals and patients across
geographies.
 The Company has a global footprint in 43 countries, world-class
manufacturing facilities in 8 countries and serves customers in over
125 countries.
 In June 2008, Ranbaxy entered into an alliance with one of the
largest Japanese innovator companies, Daiichi Sankyo Company
Ltd., to create an innovator and generic pharmaceutical
powerhouse.
 The combined entity now ranks among the top 20 pharmaceutical
companies, globally.
5/8/2012 4

5. CORPORATE HEAD OFFICE, GURGAON

6. History
 When we set out on our way in 1961, little did we realize the impact we
would make on the Indian and global pharmaceutical industry.
 Take a look at how Ranbaxy has grown through the decades......
 History
1961= Company incorporated
1973= Ranbaxy goes public
1977=Ranbaxy first joint venture in Lagos (Nigeria) is setup
1983= A modern dosage forms facility at Dewas (MP) in India goes on
Stream.
1990= Ranbaxy granted its first US Patent, for doxycline
1994=Estabilished regional headquarters in UK and USA . Listed in
Luxenburg stock exchange
2000= forays in to Brazil, the largest pharmaceutical market in South
America.
2005=Launches operations in Cannada.
2011= Celebrates golden jubilee year
5/8/2012 6

7. Financials
 For the year 2011, the Company recorded Global Sales of US
$ 2.1 Bn.
 The Company has a balanced mix of revenues from
emerging and developed markets that contribute 47% and
46% respectively.
 In 2011, North America,
1. North America, the Company's largest market contributed
sales of US $ 791 Mn,
2. Europe contributing US $ 297 Mn
3. Asia clocking sales of US $ 503 Mn.
5/8/2012 7

8. Mission/Values
 Ranbaxy's mission is 'Enriching lives globally,
with quality and affordable pharmaceuticals'.
 Values
1. Achieving customer satisfaction if fundamental
to our business
2. Provides products and services of the highest
quality
3. Ensure profitable growth and enhance wealth of
the shareholders
4. Fosters mutually beneficial relations with all our
business partners
5. Manage our operations with high concern for
safety and environment.
6. Be a responsible corporate citizen
5/8/2012 8

9. People
 The Company's business philosophy based on delivering
value to its stakeholders constantly inspires its people to
innovate, achieve excellence and set new global
benchmarks.
 Driven by the passion of it's over 14,000 strong multicultural
workforce comprising of more than 50 nationalities, Ranbaxy
continues to aggressively pursue its mission of 'Enriching
lives globally, with quality and affordable pharmaceuticals'.
 Top Management
 Dr Tsutomu Une Chairman
 Mr Arun Sawhney: CEO & Managing Director
 Independent Director
1. Dr Anthony H Wild
2. Mr Rajesh Shah
3. Mr Akihiro Watanabe
4. Mr Percy Shroff
5/8/2012 9

10. CHAIRMAN, CEO AND M.D
Dr.TsutomuUne Chairman MalvinderMohan Singh
CEO &M.D

11. Products
 The Company remains focused on ascending
the value chain in the marketing of
pharmaceutical substances and is determined
to bring in increased revenues from dosage
forms sales.
 Ranbaxy robust performance in
Cardiovasculars, Central Nervous System,
Respiratory, Dermatology, Orthopedics,
Nutritionals and Urology segments, clearly
indicates that the Company has strengthened
its presence in the fast-growing chronic and
lifestyle disease segments.
5/8/2012 11

12. PRODUCTS OFFERED
 ANTI – INFECTION
 G.I & NUTRITIONALS
 CVS & DIABETES
 CNS
 NS AID & RELATED
 ANTI ALLERGANTS
 ANTI RETROVIRALS
 UROLOGY
 OTHERS

13. Recent Acquisitions &
Alliances
Terapia (Romania)
Be-Tabs (South Africa)
Allen (Italy)
Ethimed (Belgium)
Mundogen (Spain)
Zenotech (India)
Krebs (India)
Jupiter Biosciences*(Ind.)
Cardinal Drugs (India)
Auto-injector Tech.(USA)
* Subject to due diligence

14. Major Competitors
 Sun Pharmaceuticals Industries.
 Cipla.
 Glaxo smith Kline.
 Dr. Reddy’s Laboratories
5/8/2012 14

15. Competition Analysis
Name Sales Turnover Net Profit Total Assets
Parimal Health 1,350.95 130.72 11,984.78
Dr Reddys Labs 5,249.07 893.31 7,465.00
Cipla 6,123.84 967.12 7,054.34
Sun Pharma 1,933.12 1,383.80 6,731.06
Ranbaxy Labs 7,475.90 -3,052.05 6,258.36
Lupin 4,508.50 809.98 4,135.95
Glenmark 1,154.63 212.18 3,122.86
Strides Arcolab 529.44 73.56 2,799.01
Cadila Health 2,919.88 610.38 2,653.90
Wockharth 1,754.92 -132.07 2,568.61
5/8/2012 15

16. Business Strategy
• Ranbaxy is focused on increasing the momentum in the generics business in
its key markets through organic and inorganic growth routes.
Current
• Growth is well spread across geographies with focus on developed and
emerging markets.
Focus
• Endeavour to provide a wide basket of generic and innovator products,
leveraging the unique Hybrid Business Model with Daiichi Sankyo
Hybrid Model with Daiichi Sankyo
• Focus in high growth potential segments like Vaccines and Biogenerics. (will
add significant depth to the existing product pipeline.)
New Areas
5/8/2012 16

17. Research and Development
 Ranbaxy views its R&D capabilities as a
vital component of its business strategy
that will provide a sustainable, long-term
competitive advantage. The company
has a pool of over 1,200 R&D personnel
engaged in path-breaking research.
Ranbaxy is among the few Indian
pharmaceutical companies in India to
have started its research program in the
late 70's, in support of its global
ambitions. A first-of-its-kind world class
R&D centre was commissioned in 1994
5/8/2012 17

18. R&D: Key Business strategy.
R&D is a vital
component of
business strategy
• sustainable
• long-term competitive
advantage
• over 1,200 R&D
personnel engaged
in path-breaking
research.
R&D History
• Since 1970
• first-of-its-kind world
class R&D centre
was commissioned in
1994
• dedicated facilities for
generics research
and innovative
research
Daiichi Sankyo
Group.
• Ranbaxy's New Drug
Discovery Research
(NDDR) was
transferred on July
2010
• Part of the strategy to
strengthen the global
Research and
Development
• Headquartered in
Gurgaon
5/8/2012 18

19. STRATEGIES
Ranbaxy is focused on increasing the momentum in the generics
business in its key markets through organic and inorganic growth
routes. Growth is well spread across geographies with focus on
emerging markets The Company continues to evaluate acquisition
opportunities in India, emerging and developed markets to
strengthen its business and competitiveness. Ranbaxy has forayed
into high growth potential segments like Biologics, Oncology and
injectables. These new growth areas will add significant depth to the
existing product pipeline.
The Globalization Strategy
 Growth Strategy
 Poised For Growth
 API Development And Production
 Dosage Form Development And Manufacturing
 Contract Manufacturing

20. Corporate social
Responsibility
 An essential component of Ranbaxy's
CSR is
to care for the community.
 Ranbaxy Rural Development Trust in
1978 setup Based on the theme
“Health For All”
 later re-christened as Ranbaxy
Community 5/8/2012
20

21. SWOT ANALYSIS:
STRENGTHS:
 Presence in 23 of the 27 EU countries.
 Low cost of production.
 Efficient technologies for large number of Generics.
 Large pool of skilled technical manpower both in India
and abroad.
 Increasing liberalization of government policies.
 Well developed industry with Strong manufacturing

22.  Growing incomes.
 Growing attention for health.
 New diagnoses and new social diseases.
 New therapy approaches.
 Spreading attitude for soft medication (OTC
drugs)
 Spreading use of Generic Drugs.
 Globalization
 R&D
Opportunities:

23. WEAKNESS:
 Fragmentation of installed capacities.
 Low technology level of Capital Goods of this section.
 Non-availability of major intermediaries for bulk drugs.
 Lack of experience to exploit efficiently the new patent regime.
 Low level of strategic planning for future and also for technology
forecasting.
 Production of Duplicate drugs
 Absence of Association between Institutes and Industry..

24. THREATS:
 Competition From MNCs
 Containment of rising health-care cost.
 High Cost of discovering new products and fewer
discoveries.
 Transformation of process patent to product patent.
 Stricter registration procedures.
 High entry cost in newer markets.
 High cost of sales and marketing.

25. Market Share of Ranbaxy
 Global MarketsMix 2008 54%& Emerging
The Company is currently ranked 2nd in
the Indian pharmaceutical market with 4
98%market share (IMS, Oct-D e c·09).
 Global sales in 2009 were USD 1,519 Mn
(Rs. 73,441Mn),De-growth of 9%over
previous year.
 In Rupee terms, sales grew moderately
by 1%.Sales during the Quarter recorded
growth of 25% at USD 482 Mn (Rs.
22,699 Mn). Emerging markets
accounted for54%of sales during the
year, while developed markets
5/8/2012 25

26. Ranbaxy H1 2010 Sales by Market
Emerging Markets
54%
Developed Markets
40%
Other
6%

27. CONCLUSION
 Ranbaxy is having a wide range and
good products.
 provides good facilities to their
employee.
 Company has achieved almost its
entire desire goal with its hard work
and unique idea.
 As per my opinion that RANBAXY has
a wide scope to develop in coming
years. 5/8/2012 27

28. Thank You